ANI Pharmaceuticals/$ANIP

13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX

About ANI Pharmaceuticals

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Ticker

$ANIP
Primary listing

Industry

Pharmaceuticals

Employees

897

ANIP Metrics

BasicAdvanced
$1.4B
-
-$1.15
0.56
-

What the Analysts think about ANIP

Analyst ratings (Buy, Hold, Sell) for ANI Pharmaceuticals stock.

Bulls say / Bears say

JPMorgan initiated coverage on ANI Pharmaceuticals with an 'Overweight' rating and a price target of $85, citing the company's strong portfolio and impressive 26.2% revenue growth over the last twelve months. (Investing.com)
Leerink Partners raised their price target for ANI Pharmaceuticals to $82, maintaining an 'Outperform' rating, highlighting the potential growth of Cortrophin Gel and the strategic importance of Iluvien and Yutiq. (Investing.com)
ANI Pharmaceuticals reported impressive fourth-quarter earnings, with adjusted earnings per share of $1.63, surpassing analyst estimates, and revenue of $190.6 million, marking a 44.8% increase year-over-year. (Investing.com)
Despite strong revenue growth, ANI Pharmaceuticals reported a net loss of $18.52 million over the last twelve months, indicating challenges in achieving profitability. (TipRanks)
The company's return on equity (ROE) stands at -4.32%, reflecting inefficiencies in generating profit from shareholders' equity. (TipRanks)
ANI Pharmaceuticals' operating profit margin declined to 3.6% in December 2024 from 101.7% in December 2023, suggesting increased operational costs or pricing pressures. (MarketsMojo)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

ANIP Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ANIP Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ANIP

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs